At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,902 enrolled
Drug / intervention
ClearGuard HD End Capdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
In Brief
A clinical study evaluating ClearGuard HD End Cap for End Stage Renal Disease (ESRD). Completed, enrolled 1,902 participants across 1 site.
Detailed Summary
To assess blood stream infections in participants using two FDA-cleared devices: ClearGuard HD end caps compared to the Tego® connector with the CurosTM for Tego disinfecting port protector.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease (ESRD)
CountriesUnited States
CollaboratorsDavita Clinical Research
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartNov 2015
Primary CompletionNov 2016
TodayJul 2026
First PostedOct 30, 2015
Enrollment StartNov 1, 2015
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.7 years ago
Interventions
ClearGuard HD End Capdevice
The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub